Mirxes Holding Company Limited, a micro ribonucleic acid technology company, provides diagnostic solutions for the screening of cancer, cardiovascular, metabolic, and infectious diseases accessible across Singapore and China. The company offers GASTROClear, a blood-based miRNA detection panel consisting of 12 miRNA biomarkers for gastric cancer screening; LUNGClear, a lung cancer screening product candidate; and Fortitude COVID-19 RT-qPCR test kits. It also researches, develops, and manufactures biotechnology, life, and medical science related products. The company was founded in 2014 and is headquartered in Singapore.
Metrics to compare | 2629 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship2629PeersSector | |
---|---|---|---|---|
P/E Ratio | −19.9x | −1.5x | −0.5x | |
PEG Ratio | - | −0.10 | 0.00 | |
Price/Book | 14.5x | 2.4x | 2.6x | |
Price / LTM Sales | 71.7x | 70.0x | 3.3x | |
Upside (Analyst Target) | - | 554.8% | 38.9% | |
Fair Value Upside | Unlock | −2.4% | 5.4% | Unlock |